- Home
- JFR vs SDGR Comparison
JFR vs SDGR Comparison
Compare JFR & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFR | SDGR |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | JFR | SDGR |
|---|---|---|
| Price | $7.74 | $17.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.25 |
| AVG Volume (30 Days) | 621.7K | ★ 838.4K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $256,951,000.00 |
| Revenue This Year | N/A | $23.69 |
| Revenue Next Year | N/A | $20.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.90 |
| 52 Week Low | $7.61 | $15.99 |
| 52 Week High | $8.82 | $28.47 |
Technical Indicators
Market Signals| Indicator | JFR | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 43.56 |
| Support Level | $7.71 | $17.53 |
| Resistance Level | $7.96 | $19.04 |
| Average True Range (ATR) | 0.05 | 0.74 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 10.87 | 24.77 |
Price Performance
Historical ComparisonAbout JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.